Business

Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher Concentrations and Announces Corporate Restructure

Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher Concentrations and Announces Corporate Restructure.

articleIsodiol International IncJune 27, 20185/company/isodiol-international-inc/news/isodiol-international-inc-applauds-the-fdas-decision-to-recognize-the-medical-benefits-of-cbd-at-higher-concentrations-and-announces-corporate-restructure
Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher Concentrations and Announces Corporate Restructure

About this update from Isodiol International Inc

[{"type":"text","content":"\nVANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods and the manufacturing of a pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in finished pharmaceutical products (FPPs), applauds the FDA’s decision on the long-anticipated approval of GW Pharmaceutical’s (NASDAQ: GWPH) Epidiolex for the treatment of seizures associated with two forms of epilepsy. \n “Fundamentally, the approval of Epidiolex will have no legal impact on the sale of hemp-derived CBD for consumer goods.  The fact that the FDA has stated that they will focus on proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims is welcomed by Isodiol, stated Marcos Agramont, Isodiol International, Inc. CEO.”   The company believes the FDA’s decision adds value to its Approved Pharmaceutical Ingredient (API) for finished pharmaceutical products (FPP). Much like GWPH's product that went through this extensive approval process, Isodiol can supply those interested in developing finished pharmaceutical products or conducting clinical research studies with Cannabidiol CBD the option to utilize Isodiol's API to save time and money.  Given that the FDA’s approval of Epidiolex raises the visibility of hemp-derived CBD products, it is even more critical that the U.S. Congress passes the Hemp Farming Act to permanently establish hemp and hemp-derived products as agricultural commodities in the United States.  Isodiol encourages supporters of hemp and hemp-derived CBD to use the U.S. Hemp Roundtable’s web portal to contact their Congressmen today and urge them to support the passage of the Hemp Farming Act.  CLICK HERE to send a letter to your U.S. Senators. To better situate the Company for future growth and expansion and to maximize shareholder value, the Company intends to consolidate its issued and outstanding ordinary share capital (“Common Shares”) on the basis of a one (1) post-consolidated Common Share for each (10) pre-consolidation Common Shares (the “Cons...

More updates from Isodiol International Inc